FILING ANALYSIS · THURSDAY, NOVEMBER 12
CorMedix Inc. CRMD — 8-K: Results of Operations and Financial Condition
positive
CorMedix Inc. reported Q3 2026 revenue of $54.5 million, beating street consensus, and announced the acquisition of Heron Therapeutics' assets, expected to be immediately accretive to earnings and free cash flow upon closing. The company also narrowed its adjusted EBITDA guidance and suspended 2027 DefenCath revenue guidance due to CMS reimbursement framework changes.
How we read impact: we grade every directional call in the open. Impact labels are AI estimates — not investment advice. See the full disclaimer.
Get filings like this every market day
The US SEC filings, UK RNS, EU notices, and Polymarket odds that matter — scored by AI, in one email.
Subscribe free →